Non‐serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
533 participants
Very low
Costs · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
1433 participants
Very low
30‐day mortality* · people admitted to intensive care units
It is very uncertain whether automated monitoring systems changes 30‐day mortality* compared with standard care (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Anxiety · adult ICU patients and their carers
1 finding from 1 review
Depression (lower scores mean less depression) · adult ICU patients and their carers
1 finding from 1 review
Duration of delirium Days · people with delirium
1 finding from 1 review
Children's ability to communicate effectively in everyday life: taking turns in conversation, initiating conversation and responding to others' conversational gambits · children up to 5 years of age with a communication difficulty associated with any non‐progressive motor disorder acquired before 2 years…
1 finding from 1 review
Successful treatment of exacerbation: number of participants cured. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Successful treatment of exacerbation: number of participants with P aeruginosa eradication. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Feeding with more than 50% breast milk (days) · preterm infants
1 finding from 1 review
Neonatal sepsis ≤ 3 days · preterm infants
1 finding from 1 review
Time to closure or coverage surgery · open fracture wounds
1 finding from 1 review
Number of steps per day (x 1000) at end of intervention (> 6 months post‐stroke) · increasing physical activity in adult community dwelling stroke survivors
1 finding from 1 review
Number of steps per day (x 1000) at end of intervention (< 6 months post‐stroke) · increasing physical activity in adult stroke survivors during inpatient rehabilitation
1 finding from 1 review
All‐cause mortality (up to 30 days) · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (up to 30 days) compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
Ischaemic events: peripheral thrombosis, cerebral myocardial infarction (within 30 days of surgery) · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in ischaemic events: peripheral thrombosis, cerebral myocardial… compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review